Iveric Bio to Present at Upcoming Investor Conferences

Iveric Bio (NASDAQ: ISEE) announced its executives, Glenn P. Sblendorio and Pravin U. Dugel, M.D., will participate in two investor conferences this September.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

09/07/2022 - 08:00 AM EDT

PARSIPPANY, N.J.--(BUSINESS WIRE)-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer, and Pravin U. Dugel, M.D., President, will participate in fireside chats at the following two investor conferences in September:

Wells Fargo 2022 Healthcare Conference
- Date: September 9, 2022
- Time: 10:25 a.m. Eastern Time
Morgan Stanley 20^th Annual Global Healthcare Conference
- Date: September 12, 2022
- Time: 2:50 p.m. Eastern Time

Investors and the general public are invited to access the live webcasts of the fireside chats on the Investor / Events & Presentations section of the Iveric Bio website at www.ivericbio.com. An archived replay of both presentations will be available on the Company’s website immediately following each conference and for at least 30 days thereafter.

About Iveric Bio
Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retinal diseases including earlier stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.

Forward-looking Statements
Any statements in this press release or made during the presentation referenced herein about Iveric Bio’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including those described in the “Risk Factors” section of public filings made by Iveric Bio with the U.S. Securities and Exchange Commission. Any forward-looking statements represent Iveric Bio’s views only as of the date of this press release or the presentation, as applicable. Iveric Bio anticipates that subsequent events and developments may cause its views to change. While Iveric Bio may elect to update these forward-looking statements at some point in the future, Iveric Bio specifically disclaims any obligation to do so unless required by law.